(UroToday.com) Nivolumab (anti-PD-1 antibody) and cabozantinib (tyrosine kinase inhibitor of MET, VEGFR, AXL, and others) each have single-agent activity in advanced renal cell carcinoma based on the CABOSUN, METEOR and CheckMate 025 studies. A recent phase 1 study in advanced genitourinary malignancies supported the activity and relative safety of combining these two drugs, leading to the creation of the randomized phase 3 CheckMate 9ER trial (NCT03141177).